» Articles » PMID: 21108616

Ocular Manifestation of Rheumatoid Arthritis-different Forms and Frequency

Overview
Specialty General Medicine
Date 2010 Nov 27
PMID 21108616
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Rheumatoid arthritis (RA) is a systemic inflammatory disease associated with a number of extra-articular organ manifestations. Ocular manifestations involved with RA are keratoconjunctivitis sicca, episcleritis, scleritis , corneal changes, and retinal vasculitus. The etiopathogenesis of this autoimmune disorder is still unknown. Aim of our study was to present different ocular manifestations of RA and their frequency. We have examined 691 patient with the diagnoses of RA. All examined patients were in I or II stage of the disease according to criteria of The American College of Rheumatology. Ophthalmological exam obtained: visual acuity by Snellen sings, biomicroscopy of anterior segment, Schirmer test, tear break-up time (BUT), applanation tonometry and indirect ophthalmoscopy. In all patients with retinal vasculitis fotofundus and in indicated cases fluorescein angiography was preformed. The most common manifestation of ocular involvement was keratoconjunctivitis sicca. Episcleritis was diagnosed in 5.06% patients with RA, while scleritis was present in 2.06% of patients. Diffuse scleritis was present in one patient, while nodular was present in 13 patients. There were no patients with posterior or necrotizing scleritis among examined patients. Sclerosing keratitis was diagnosed in 11 female patients. It is characterized with peripheral thickening and opacification of the stroma adjacent to the site of inflammation. Posterior scleritis or scleromalacia of cornea was not present in our patients, because all of them were in I or II stage of disease. Retinal vasculitis was present in three patients, two male and one female patient (0.45%). Ocular manifestation was present in 27.2% of patients. Women were more affected.

Citing Articles

Is there a paradoxical side effect? Is it a case of inefficiency? Peripheral ulcerative keratitis in a patient with rheumatoid arthritis in remission treated with tocilizumab.

Tombak Y, Sezer M, Bal A, Eksioglu E, Dulgeroglu D Turk J Phys Med Rehabil. 2024; 70(1):142-144.

PMID: 38549824 PMC: 10966751. DOI: 10.5606/tftrd.2023.11091.


Choroidal, retinal, and optic nerve changes in rheumatoid arthritis and primary sjogren's syndrome patients: comparıson with each other and healthy subjects.

Kiyat P, Karti O, Gercik O, Sak T Int Ophthalmol. 2024; 44(1):24.

PMID: 38324105 DOI: 10.1007/s10792-024-02970-9.


Ocular involvement in rheumatic diseases.

Dankiewicz-Fares I, Jeka D, Barczynska T Reumatologia. 2023; 61(5):389-394.

PMID: 37970118 PMC: 10634405. DOI: 10.5114/reum/172767.


Overview of Rheumatoid Arthritis and Scientific Understanding of the Disease.

Jahid M, Khan K, Rehan-Ul-Haq , Ahmed R Mediterr J Rheumatol. 2023; 34(3):284-291.

PMID: 37941854 PMC: 10628871. DOI: 10.31138/mjr.20230801.oo.


Ocular disease as the presenting sign of rheumatoid arthritis - An observational case series.

Ravulaparthi G, Bandla B, Visala N Indian J Ophthalmol. 2023; 71(4):1647-1651.

PMID: 37026317 PMC: 10276698. DOI: 10.4103/IJO.IJO_2765_22.


References
1.
Lin C, Shih M, Su C . Scleritis. Surv Ophthalmol. 2006; 51(3):288-9. DOI: 10.1016/j.survophthal.2006.02.011. View

2.
Papaliodis G, Chu D, Foster C . Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology. 2003; 110(4):786-9. DOI: 10.1016/S0161-6420(02)01932-2. View

3.
Sobrin L, Kim E, Christen W, Papadaki T, Letko E, Foster C . Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol. 2007; 125(7):895-900. DOI: 10.1001/archopht.125.7.895. View

4.
Lilleby V, Gran J . [Systemic rheumatoid arthritis]. Tidsskr Nor Laegeforen. 1998; 117(29):4223-5. View

5.
Wakefield D, McCluskey P . Cyclosporin therapy for severe scleritis. Br J Ophthalmol. 1989; 73(9):743-6. PMC: 1041870. DOI: 10.1136/bjo.73.9.743. View